Clear Cell Renal Cell Carcinoma Ccrcc clinical trials

Explore recruiting clear cell renal cell carcinoma ccrcc clinical trials.

Recruiting clear cell renal cell carcinoma ccrcc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Clear Cell Renal Cell Carcinoma Ccrcc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EORTC-2361-GUCG: Phase II trial evaluating the efficacy of 177Lutetium-PSMA treatment in patients with metastatic clear cell Renal Carcinoma Cell with progressive disease on first-line or second-line systemic treatment (RENALUT)

Spain, France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Germany, France, Denmark, Sweden, Finland, Romania +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with CAIX-positive cancer

Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

Hungary, Finland, Sweden, Netherlands, Ireland, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies

Italy, Spain, Germany, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Kidney cancer

Sweden, France, Portugal, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Clear Cell Renal Cell Carcinoma Ccrcc trials by city

Clear Cell Renal Cell Carcinoma Ccrcc in Toronto Clear Cell Renal Cell Carcinoma Ccrcc in Vancouver Clear Cell Renal Cell Carcinoma Ccrcc in Montreal Clear Cell Renal Cell Carcinoma Ccrcc in Calgary Clear Cell Renal Cell Carcinoma Ccrcc in Edmonton Clear Cell Renal Cell Carcinoma Ccrcc in Ottawa Clear Cell Renal Cell Carcinoma Ccrcc in Winnipeg Clear Cell Renal Cell Carcinoma Ccrcc in Quebec City Clear Cell Renal Cell Carcinoma Ccrcc in Hamilton Clear Cell Renal Cell Carcinoma Ccrcc in Kitchener Clear Cell Renal Cell Carcinoma Ccrcc in London Clear Cell Renal Cell Carcinoma Ccrcc in Halifax Clear Cell Renal Cell Carcinoma Ccrcc in New York Clear Cell Renal Cell Carcinoma Ccrcc in Los Angeles Clear Cell Renal Cell Carcinoma Ccrcc in Chicago Clear Cell Renal Cell Carcinoma Ccrcc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease